AstraZeneca reported preliminary Western-patient data for its dual-target CAR‑T showing response rates consistent with earlier China-only studies, according to ASH disclosures. Early investigators emphasized comparable efficacy signals across populations and continued enrollment into pivotal studies. AstraZeneca framed the data as validation of its dual-antigen targeting strategy and a step toward global development, while noting further follow-up is required to define durability and safety profiles across broader patient cohorts.